Procavea obtains funding to boost its novel delivery platform for RNA therapeutics
Summary
The CHF 150,000 from Venture Kick will allow the startup to validate the platform for siRNA applications.The global RNA therapeutics market is large, forecast to exceed USD 30 billion by the end of this decade with an astonishing annual growth rate of 18%. Besides providing effective vaccines in record times, RNA therapeutics, such as small interfering RNAs (siRNA), have shown great potential to treat many diseases with a high unmet medical need. Among the advantages, these protein cages are non-toxic, biodegradable, compatible with a wide range of cargo, and can be targeted to specific cell types. These proceeds from this round will be used to bring Procaveas lead candidate through preclinical development within the next two years, laying the groundwork for initiating a first clinical study.Dr. Procavea recently initiated a collaboration at ETH with Prof. Markus Stoffel, a key opinion leader in the field of metabolic diseases and siRNA therapeutics.In our journey so far, the Venture Kick program has been a precious experience.